FILING ANALYSIS · MONDAY, NOVEMBER 16

MapLight Therapeutics, Inc. MPLT — 8-K: Results of Operations and Financial Condition

neutral

MapLight Therapeutics reported a strong cash position of $463.4 million, which is expected to fund operations through key clinical readouts and through 2028, and announced plans to advance ML-007C-MA into a Phase 3 trial for schizophrenia and a Phase 2 trial for Alzheimer's disease psychosis, but no quantified surprises were disclosed in the filing.

The filing

8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+